biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Protalix

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Feb 25, 2023 9:56am

74 Views

Post# 35305070

RE:RE:RE:Protalix

"The outcome could be bankruptcy to significant surprise."

Well not directly to bankruptcy. BTI would apply to the Court for protection under the "Companies' Creditors Arrangement Act" (CCAA). Stranger things have happened to companies in that type of situation.

"Also, the J&J multi-product option appears to have progressed."

Progressed into what exactly?

G1945V

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale